CervoMed Inc.
Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $1.50
- 52-Week Range
- $1.27 – $10.00
- Market Cap
- $21.94M
- P/E (TTM)
- —
- EPS (TTM)
- -2.65
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 1.26
- PEG Ratio
- —
- Return on Equity
- -131.52%
- Return on Assets
- -70.33%
- Gross Margin
- 0.00%
- Operating Margin
- -334924.88%
- Profit Margin
- 0.00%
- Current Ratio
- 5.37
- Debt/Equity
- —
- Total Debt
- $0.00
- Free Cash Flow
- $-15.99M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $2.34M
Market Snapshot
About
CervoMed Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. Headquartered in Rockville, Maryland, the company is advancing neflamapimod, a selective p38 alpha kinase inhibitor, as a potential therapy for dementia with Lewy bodies (DLB) and other neurological conditions. CervoMed's drug candidate targets neuroinflammation, a key factor in neurodegenerative disease progression. The company was formerly known as Cerevance and rebranded following its strategic focus on neflamapimod development.